Zoetis (ZTS) Q1 2025: Companion Animal Franchises Drive 14% Growth as Retail Channel Hits 21% of U.S. Sales

2025-05-06 | By EarningsIQ Research

Zoetis delivered robust double-digit growth in its core animal health franchises, powered by international strength and a surging U.S. retail channel, but faces near-term margin pressure from tariffs and gradual adoption of new pain therapies. Strategic investments in education and innovation are setting the stage for future category expansion, even as consumer spending and regulatory uncertainty create a complex backdrop. Management’s steady guidance signals confidence in the durability of the business model, with a watchful eye on evolving tariff and competitive dynamics.

Summary

• Retail Channel Expansion: U.S. retail and home delivery now represent 21% of sales, accelerating compliance and lifetime value.
• Franchise Diversification: Companion animal, livestock, and international segments all contributed to balanced growth.
• Tariff and Competition Watch: Management is proactively managing cost headwinds and new entrants, leveraging a diversified supply chain.

Performance Analysis

Zoetis posted 9% organic operational revenue growth, led by international markets at 11% and a resilient 6% in the U.S. (excluding the MFA divestiture, a strategic exit from medicated feed additives). The companion animal portfolio, which now accounts for roughly two-thirds of total revenue, grew 9% operationally, while livestock delivered 7% organic growth globally, but faced a modest 2% U.S. decline due to price competition and supply timing.

Key franchises drove the quarter: Semperica, the company’s broad-spectrum parasiticide, surged 19% globally and 17% in the U.S., benefiting from a first-mover advantage and strong retail uptake. Dermatology (Apoquel, Cytopoint) achieved 10% global growth and continues to convert customers to chewable formats, improving compliance. The osteoarthritis (OA) pain franchise (Librela, Solensia) increased 15% globally, though U.S. adoption remains gradual as education and real-world data campaigns ramp up. Retail and alternative channels grew 40% in the U.S., now representing 21% of the business, driven by consumer preference for convenience and auto-ship programs.

• International Outperformance: Companion animal and livestock both posted double-digit growth, with Semperica and dermatology leading share gains in Europe and Latin America.
• Margin Dynamics: Adjusted gross margin declined ex-FX due to higher manufacturing costs and product mix, partially offset by the MFA divestiture.
• Expense Discipline: Operating expense growth was contained, with S&A up 4% operationally and R&D down 2% on timing.

Net income growth of 6% operationally (organic) outpaced revenue, though reported EPS benefited further from FX tailwinds and share buybacks. Management reaffirmed confidence in the outlook, citing the resilience of animal health demand and the company’s diversified model.

Executive Commentary

Strategic Positioning

1. First-Mover Advantage in Key Franchises

Zoetis’s early entry into parasiticides and dermatology has allowed it to establish dominant positions, with Semperica and Apoquel/Cytopoint still gaining share even as competitors enter. The company now holds a 40% share in puppies for Semperica and over 90% satisfaction rates in dermatology, underlining sticky customer relationships and high barriers to switching.

2. Retail and Omnichannel Expansion

Retail and home delivery channels have become critical growth engines, now comprising 21% of U.S. sales and growing at 40%. Auto-ship programs and direct-to-consumer advertising are increasing compliance and customer lifetime value, while Amazon’s entry is expected to further accelerate channel shift rather than disrupt pricing or margins.

3. OA Pain Franchise: Building a New Category

Librela and Solensia are creating a new market for monoclonal antibody OA pain management, with double-digit growth and 25 million doses distributed globally. Uptake is slower than initially forecast, especially in the U.S., due to the need for medical education and gradual consumer adoption. Zoetis is investing in post-launch studies, KOL engagement, and targeted campaigns to expand the addressable market, with a long-acting, three-month injection on track for approval this year.

4. Supply Chain and Tariff Mitigation

Zoetis’s global manufacturing footprint, with 60% of production in the U.S., provides flexibility to manage tariff exposure. Current guidance includes only enacted tariffs (mainly on APIs and select diagnostics from China), while the company actively lobbies for animal health exemptions and leverages inventory and sourcing strategies to mitigate risk.

5. Livestock Resilience and Vaccine Innovation

Despite the MFA divestiture, livestock remains a core pillar, with strong international growth and new solutions such as the USDA-licensed avian influenza vaccine. The segment’s performance underscores the company’s ability to adapt to changing protein demand and regulatory landscapes.

Key Considerations

This quarter’s results highlight the importance of portfolio diversification and channel agility as Zoetis navigates evolving consumer, regulatory, and competitive forces.

Key Considerations:

• Channel Shift Momentum: Retail and home delivery channels are reshaping how pet owners access care, increasing compliance and stickiness.
• Innovation Pipeline Depth: Upcoming launches, including a long-acting OA antibody, could unlock new multi-billion dollar opportunities.
• Tariff and Regulatory Volatility: Active scenario planning and a U.S.-centric supply chain provide insulation, but future trade policy remains a wild card.
• Consumer Spending Sensitivity: Gradual adoption of new chronic therapies reflects broader economic caution, but the essential nature of animal health supports baseline demand.
• Competitive Entrant Dynamics: New products from rivals are accelerating market expansion rather than eroding Zoetis’s share, especially in combination therapies.

Risks

Tariff escalation and shifting trade policy present tangible cost risks, especially for API sourcing and cross-border diagnostics. Gradual consumer adoption of high-value therapies could delay full realization of OA market potential, while new competitive entrants in dermatology and parasiticides may pressure price or promotional activity. Regulatory slowdowns, although not yet observed, remain a watchpoint given FDA resource constraints.

Forward Outlook

For Q2 2025, Zoetis guided to:

• Continued organic operational revenue growth of 6% to 8% for the full year
• Adjusted net income growth of 5% to 7% organic operationally, reflecting enacted tariffs

For full-year 2025, management maintained core revenue guidance and updated net income to reflect tariff headwinds. Key drivers for the rest of the year include:

• Double-digit growth from Semperica, dermatology, and OA pain franchises
• Mitigation of further tariff impacts through supply chain flexibility
• Continued channel shift and retail expansion, with alternative channels expected to grow as a share of U.S. sales

Takeaways

Zoetis’s core franchises and retail channel expansion are driving resilient growth, even as margin headwinds and gradual OA adoption temper near-term upside.

• Channel Innovation: Retail and home delivery are accelerating compliance, reshaping the revenue mix, and positioning Zoetis for future consumer trends.
• Execution Discipline: The company’s diversified supply chain and proactive tariff mitigation underscore operational strength in a volatile environment.
• Pipeline Leverage: Investors should watch the launch and ramp of long-acting OA therapies and further retail penetration as key growth levers in coming quarters.

Conclusion

Zoetis’s Q1 results reinforce its status as a global leader in animal health, with innovation, channel agility, and a diversified model supporting both resilience and future growth. While tariffs and gradual OA adoption are near-term watchpoints, the company’s strategic investments and operational discipline provide a strong foundation for continued outperformance.

Industry Read-Through

The animal health sector’s ability to deliver steady growth in volatile macro conditions highlights its essential, recession-resistant characteristics. The rapid expansion of retail and alternative channels is a secular trend likely to reshape distribution and compliance models across the industry, with implications for both legacy players and new entrants. Tariff risk and supply chain localization are rising priorities, while innovation in chronic care and diagnostics remains a key battleground. Competitors should note the importance of first-mover advantage and the stickiness of established franchises, as well as the need for deep educational investments to unlock new therapy categories.

ZTS Healthcare Animal Health Omnichannel Retail Tariffs Companion Animal Innovation